A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer

Sunela, Kaisa; Koskinen, Sanna; Kellokumpu-Lehtinen, Pirkko-Liisa

doi:10.1007/s00280-009-1134-2

Cited by 12 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…G3-4 toxicity was observed in 46% of patients, requiring dose reduction in 85% of patients. The authors concluded that this combination treatment has moderate, but manageable toxicity and can be interesting in selected patients [54].…”

Section: Chemoimmunotherapymentioning

confidence: 98%

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

et al. 2013

View full text Add to dashboard Cite

The prognosis of patients affected by metastatic renal cell carcinoma (mRCC) has improved markedly with targeted therapies. Unfortunately, 20-25% of the patients are refractory to treatment at the first response assessment and most patients will acquire drug resistance during the treatment. Moreover, current data on the clinical activity of targeted agents in poor risk or non-clear-cell mRCC patients are inconclusive because of the absence of prospective trials. Therefore, there are still several patients in need of new therapeutic approaches to improve clinical outcomes. Kidney cancer is historically considered resistant to chemotherapy on the basis that the results of phase II trials have not always been promising. We carried out a systematic review of both monochemotherapy and polychemotherapy alone or combined with immunotherapy or targeted agents in mRCC to define the state of the art and to evaluate further clinical research fields. All retrospectives, phase I/dose finding, phase II and phase III studies on chemotherapy in mRCC, published in the literature from January 2003 to November 2012, with at least 20 patients enrolled, were evaluated. Although the results of clinical trials have often been disappointing, in selected cases of mRCC, chemotherapy may have a promising antitumor activity, particularly when there are sarcomatoid differentiation features, or in highly progressive disease where the combination of doxorubicine plus gemcitabine or capecitabine has yielded interesting results. Chemotherapy may play a role in mRCC, whereas targeted agents and immunotherapy have not yielded durable and satisfactory results; further studies are needed.

show abstract

Section: Chemoimmunotherapymentioning

confidence: 98%

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The observed five-year survival is approximately 75-80% for stage T1, 55% for T2, 40% for T3, and 20-30% for T4 (Sunela et al 2009, Tsui et al 2000. For patients with stage I disease (tumor confined to the kidney) the five-year survival is approximately 90%, and for those with stage I and histologic of chromophobe type it is almost 100% (Zisman et al 2001).…”

Section: Pathological Tumor Stagingmentioning

confidence: 82%

Prognostic Factors in Renal Cell Carcinoma: An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions

Kankuri-Tammilehto¹

2012

Emerging Research and Treatments in Renal Cell Carcinoma

View full text Add to dashboard Cite

“…Pathological tumor stage (T-stage) has been observed to be the most important factor for locally confined RCC in predicting the survival of patients who have undergone nephrectomy (Kankuri et al 2006, Delahunt et al 2002. The observed five-year survival is approximately 75-80% for stage T1, 55% for T2, 40% for T3, and 20-30% for T4 (Sunela et al 2009, Tsui et al 2000. For patients with stage I disease (tumor confined to the kidney) the five-year survival is approximately 90%, and for those with stage I and histologic of chromophobe type it is almost 100% (Zisman et al 2001).…”

Section: Staging and Prognostic Factors In Rcc 21 Pathological Tumor Stagingmentioning

confidence: 98%

Emerging Research and Treatments in Renal Cell Carcinoma

Amato¹

2012

View full text Add to dashboard Cite

Texas before becoming a fellow in Medical Oncology at MD Anderson Cancer Center. Dr. Amato is one of the world's leading experts in the treatment of genitourinary cancer. Early in his career, his research helped make testicular cancer a highly treatable disease. His current research focuses on molecular-targeted therapeutics, halting the progression of metastatic kidney and prostate cancers, the further development of immunotherapies, and determining how his studies may be used to treat genitourinary cancer.

show abstract

A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer

Cited by 12 publications

References 35 publications

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

Prognostic Factors in Renal Cell Carcinoma: An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions

Emerging Research and Treatments in Renal Cell Carcinoma

Contact Info

Product

Resources

About